A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Phase 2

Active, not recruiting

• Conditions: Sinusitis; Nasal Polyps; Polyps
• Interventions: Drug: 611; Drug: Placebo

• Registration Number: NCT05865496
• Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Brief Summary

This study will evaluate the effect and safety of 611 in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).

Detailed Description

The main purpose is to evaluate the effect of 611 on a background of mometasone furoate nasal spray (MFNS) in reducing endoscopic nasal polyp score (NPS) and nasal congestion/obstruction score (NCS) severity in eligible patients with CRSwNP whose disease remains inadequately controlled despite daily treatment with intranasal corticosteroid (INCS) therapy in comparison to placebo.

Study Timeline

• Study First Submitted: 2023-04-25
• Study First Submitted QC: 2023-05-15
• Study First Posted: 2023-05-19
• Study Start: 2023-06-30
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-10
• Last Update Posted: 2024-01-12
• Primary Completion: 2024-05-31
• Study Completion: 2024-07-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

1. Female and male patients aged ≥18 and ≤ 75 years at the time of screening.
2. Bilateral CRSwNP.
3. Bilateral NPS of ≥5 with a minimum score of 2 in each nasal cavity
4. Nasal Congestion Score of > 2 at screening and a weekly average severity of > 1 at time of randomization.
5. Patients whose bilateral sino-nasal polyposis remains inadequately controlled despite prior treatment with SCS anytime within the past 2 years; and/or had a medical contraindication/intolerance to SCS; and/or received nasal polyp surgery 6 months before signing the ICF.

Exclusion Criteria

1. Patients with other nasal diseases or symptoms.
2. Patients who are taking or have taken the following prohibited therapies as specified, e.g., systemic steroids within 4 weeks prior to screening, less than 3 months or 5 half-lives for biologic therapy prior to screening.
3. Patients who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.
4. History of cancer.
5. Known or suspected history of immunosuppression.
6. Known with allergic or intolerant to mometasone furoate spray or 611/placebo.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
611 Dose A	611	611 300 mg Q2W, subcutaneous (SC) injection.
611 Dose B	611	611 450 mg Q4W, subcutaneous (SC) injection.
Placebo	Placebo	Placebo subcutaneous (SC) injection.

Primary Outcome Measures

Name	Time	Method
Change From Baseline at Week 16 in Bilateral Nasal Polyp Score (NPS)	Up to 16 weeks	NPS is evaluated by nasal endoscopy. For each nostril, NPS is graded based on polyp size from 0 = no polyps to 4 = large polyps causing complete obstruction of inferior nasal cavity; lower score = smaller sized polyps. Bilateral NPS is the sum of right and left nostril scores, ranges from 0 (no polyps) to 8 (large polyps), higher score = more severe disease.
Change From Baseline at Week 16 in Nasal Congestion Symptom Severity Score (NCS)	Up to 16 weeks	NCS is assessed by the participants daily from visit 1 and throughout the study on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicates more severity.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline to the End of study in Lund Mackay Score	Up to 16 weeks	The Lund Mackay Score scoring system rates each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score is the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease.
Change From Baseline to the End of study in Total Nasal Symptom Score (TNSS)	Up to 16 weeks	TNSS is a composite of nasal congestion, loss of smell, and rhinorrhea (anterior/posterior nasal discharge), each access on 0-3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms). Total score ranges from 0 (no symptoms) to 12 (severe symptoms). Higher score indicated more severe symptoms.
Change From Baseline to the End of study in the University of Pennsylvania Smell Identification Test (UPSIT) Score	Up to 16 weeks	The UPSIT is a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia) to 40 (normal sense of smell), lower score indicated severe smell loss.
Change From Baseline to the End of study in 22-item Sino-nasal Outcome Test (SNOT-22) Scores	Up to 16 weeks	The SNOT-22 is a validated questionnaire that used to assess the impact of chronic rhinosinusitis phenotype with nasal polyps (CRSwNP) on health-related quality of life (HRQoL). It is a 22 item questionnaire with each item assigned a score ranging from 0 (no problem) to 5 (problem as bad as it can be). The total score may range from 0 (no disease) to 110 (worst disease), lower scores representing better health related quality of life.
611 Concentration in Serum	Up to 24 weeks	The concentration of 611 in Serum.

Trial Locations

Locations (4)

Site 02; 🇨🇳 Xuzhou, Jiangsu, China

Site 01; 🇨🇳 Beijing, Beijing, China

Site 03; 🇨🇳 Beijing, Beijing, China

Site 04; 🇨🇳 Wuhan, Hubei, China